Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)

Nicola Cooper, Waleed Ghanima, Francesco Zaja, Lei Zhang, Yoshitaka Miyakawa, Marie Luise Hütter-Krönke, Matias Cordoba, Mattea Orsini, Imene Gouia, Ahmed Daak, Howard Liebman

Blood (2025) 146 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2025-1254

Published: 2025

Journal Articles

Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)

David Kuter, Waleed Ghanima, Nicola Cooper, Marie Luise Hütter-Krönke, Guillaume Moulis, Francesco Zaja, Maria Cristina Pascual Izquierdo, Howard Liebman, Sandhya Panch, Hisashi Kato, Matias Cordoba, Ahmed Daak, Maria Belen Rodriguez

Blood (2025) 146 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2025-4827

Published: 2025

Journal Articles

Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy

Philip Choi, Charlotte Bradbury, Tomas Jose Gonzalez-Lopez, Muhlis Cem Ar, Karolin Trautmann-Grill, Mathias Rummel, Alessandra Borchiellini, Nicola Cooper, Fernando Chuliber, Rushad Patell, Blanca Sanchez, Patrick Urban, Alex Allepuz, Fabienne Le Gac, Renxin Lin, David Kuter

Blood (2025) 146 (Supplement 1): 844.

https://doi.org/10.1182/blood-2025-844

Published: 2025

Journal Articles

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Francesco Zaja, Adam Cuker, Hanny Al-Samkari, Marc Michel, Yogesh Chattar, Matthew Foster, Meritxell Vendranas, Nicola Cooper

Blood (2025) 146 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2025-6586

Published: 2025

Journal Articles

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Alessandro Lucchesi, Nicola Cooper, Bruno Fattizzo, Lei Wang, Eric Boitier, Cintia C. Palu, Dimitri Carene, Vincent Mikol, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2025-2881

Published: 2025

Journal Articles

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

David Kuter, Nicola Cooper, Mattea Orsini, Jerome Msihid, Laurence Pollissard, Matias Cordoba, Ahmed Daak, Marek Wardecki, Lei Wang, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2025-1105

Published: 2025

Journal Articles

Pre-treatment immune profiling by flow cytometry and single-cell transcriptomics identifies distinct features in B and T cells in rituximab responders and non-responders

Alicia Au, Michelle MH Tan, Akhil Khera, Amna Malik, Nehal Joshi, Lucy Kamuriwo, Rocel Saputil, Spencer Mackie, Cynthia Lee, Camelia Vladescu, Bridget Chivers, Tung Le, Patrick Urban, Tiffany Loy, Andreas Bruederle, Nicola Cooper

Blood (2025) 146 (Supplement 1): 734.

https://doi.org/10.1182/blood-2025-734

Published: 2025

Journal Articles

Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study

Michele Lambert, Nicola Cooper, Maria Cristina Pascual Izquierdo, Elisa Lucchini, Sylvain Audia, Huafang Wang, Yoshitaka Miyakawa, Meredith Foster, Maria Belen Rodriguez, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2025-3027

Published: 2025

Journal Articles

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, Bing Han, Catherine Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, Míriam Vara Pampliega, Deepthi Jayawardene, Heidi Krenz, Jing Zhao, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2025-4655

Published: 2025

Journal Articles

GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia

Blood (2025) 146 (Supplement 1): 1368.

https://doi.org/10.1182/blood-2025-1368

Published: 2025

Journal Articles

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

David Kuter, Chen Yunfei, Nicola Cooper, Waleed Ghanima, Hisashi Kato, Yoshiaki Tomiyama, Raymond Wong, Renchi Yang, Cheryl Li, Emily Skelton, Scarlett Wang, Donald Yee, Parth Patwari

Blood (2025) 146 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2025-3049

Published: 2025

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John D. Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael Tarantino, Nicola Cooper, MA, MD MRCP, FRCPath, Donald Beam, Jenny M. Despotovic, DO, MS, Alexey Maschan, MD PhD Professor, Nancy Carpenter, Melissa Eisen, Joseph Park

Blood (2017) 130 (Supplement 1): 2334.

https://doi.org/10.1182/blood.V130.Suppl_1.2334.2334

Published: 2017

Journal Articles

Rituximab Does Not Increase the Complication Rate, Particularly Perforation, When Added to Chemotherapy for Patients with Primary B-Cell Lymphomas of the Gastrointestinal Tract.

Shireen A. Kassam, MRCP, Anthony H. Goldstone, FRCP, A. V. Hoffbrand, FRCP, Miguel Perez-Machado, MBBS, Nicola Cooper, MRCP, Panos Kottaridis, MRCP, Archie Prentice, FRCP, Derralyn Hughes, MRCP, Christopher J. McNamara, FRACP, FRCPA

Blood (2005) 106 (11): 4742.

https://doi.org/10.1182/blood.V106.11.4742.4742

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)

Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)

Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy

Ianalumab retreatment in adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who benefitted from previous ianalumab treatment: A phase 2 exploratory study

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

Pre-treatment immune profiling by flow cytometry and single-cell transcriptomics identifies distinct features in B and T cells in rituximab responders and non-responders

Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Rituximab Does Not Increase the Complication Rate, Particularly Perforation, When Added to Chemotherapy for Patients with Primary B-Cell Lymphomas of the Gastrointestinal Tract.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only